dpp4 glp 1 combination The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs | Cardiovascular Diabetology Insights into the Roles of

Broglio F, Prodam F, Gottero C, Destefanis S, Me E, Riganti F, Giordano R, Picu A, Balbo M, Van der Lely AJ, Ghigo E, Arvat E

01 Schedule Your Weight Loss Consult Book a virtual or in-office consultation to discuss your health history and goals

Efficacy magnitude Clinical trials show GLP-1 agonists produce substantial HbA1c reductions (typically 1.01.5% depending on agent and dose) and weight loss (515% of body weight with higher doses)

NR4A1 inhibits the ubiquitination degradation of P53 by regulating the downstream target gene MDM2, thereby affecting the oxidative respiration process of mitochondria, producing oxidized lipids, and inducing ferroptosis in cells